Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β<sub>2</sub>-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells

Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β₂-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells

H. Boushey, P. Woodruff, G. Dolganov, P. Dorinsky, J. Fahy (San Francisco, Raleigh, United States Of America)

Source: Annual Congress 2003 - Advances in our understanding of corticosteroids in the treatment of asthma

Session: Advances in our understanding of corticosteroids in the treatment of asthma
Session type: Poster Discussion
Number: 347

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Boushey, P. Woodruff, G. Dolganov, P. Dorinsky, J. Fahy (San Francisco, Raleigh, United States Of America). Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β₂-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells. Eur Respir J 2003; 22: Suppl. 45, 347

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
Effect of add-on montelukast to inhaled corticosteroids on excessive airway narrowing in adult asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
The effect of inhaled corticosteroids on airway mast cells in type 2 low asthma Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol Source: International Congress 2019 – Airway physiology Year: 2019
Effects of intervention with high-dose inhaled corticosteroids on airway remodelling in diagnosed genetic variants of IL13 with asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge Source: Eur Respir J 2007; 30: Suppl. 51, 749s Year: 2007
Inhaled corticosteroid (ICS) induced metabolome changes in asthmatics. Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β₂agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Source: Eur Respir J 2002; 20: 873-879 Year: 2002
E-cadherin (CDH-1) polymorphisms associate with airway remodeling, inflammation and FEV₁decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β₂ agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myfibroblasts Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007

Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells

Share or cite this content

Member's Comments

Related content which might interest you:

Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β₂-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells